Hesperidin

Hesperidin's primary pharmacology runs through the vascular endothelium, with secondary activity at several anti-inflammatory and metabolic nodes. Because the native glycoside is poorly absorbed, the molecule that actually reaches systemic circulation after oral dosing is hesperetin aglycone (and its phase-II conjugates, primarily hesperetin-7-O-glucuronide and hesperetin-3'-sulfate), which are produced after colonic bacterial α-rhamnosidase and β-glucosidase cleave the rutinose sugar. This explains why hesperidin Cmax typically occurs 5–7 hours after oral dosing rather than the 1–2 hour timeframe expected for a typical small molecule — the molecule must transit the small intestine relatively intact before bacterial hydrolysis unlocks the aglycone. Micronization (Daflon/MPFF), enzymatic pre-conversion to 2S-hesperidin (hesperidin-2-glucoside / Cardiose), and phytosome complexation all shortcut this bottleneck by either exposing more surface area for bacterial hydrolysis or bypassing the rhamnosidase step entirely.

Once hesperetin conjugates reach the endothelium, the dominant mechanistic node is nitric oxide signaling. Hesperetin upregulates endothelial nitric oxide synthase (eNOS) transcript and protein expression, enhances eNOS phosphorylation at Ser1177 (the activating site), and reduces NADPH-oxidase-derived superoxide, which otherwise would scavenge NO and produce peroxynitrite. The net result is more bioavailable NO, better relaxation of vascular smooth muscle, and the flow-mediated dilation improvements captured in Morand 2011, Buscemi 2012, Rizza 2011, and Salden 2016. Hesperidin also appears to upregulate heme oxygenase-1 (HO-1) modestly via Nrf2 — the same Nrf2/Keap1/ARE pathway described in depth on the sulforaphane page, though hesperetin is a far weaker Nrf2 activator than sulforaphane and the effect is unlikely to be clinically meaningful at typical supplemental doses.

The second mechanistic branch is anti-inflammatory activity at the leukocyte–endothelium interface. Milenkovic 2011's transcriptomic analysis of peripheral blood mononuclear cells after a single 500 mg hesperidin dose in healthy volunteers showed the largest gene-expression signatures in inflammation and leukocyte transendothelial migration pathways, with reductions in ICAM-1, VCAM-1, E-selectin, and monocyte chemoattractant protein-1 (MCP-1) expression. This maps mechanistically onto the vein-wall stabilization achieved by MPFF in chronic venous insufficiency — the core venous-disease pathology is valve dysfunction leading to venous hypertension, which recruits leukocytes to the vein wall, which then release proteases that damage valves further and increase capillary permeability, producing the edema and aching of CVI. Hesperidin/diosmin interrupt this cycle by reducing leukocyte adhesion and by mildly stabilizing capillary permeability.

A third, smaller mechanistic node is lipid metabolism. Hesperidin weakly inhibits intestinal cholesterol absorption (via NPC1L1 modulation in preclinical models), mildly upregulates hepatic LDL receptor expression, and reduces hepatic SREBP-1c-driven lipogenesis. The clinical magnitude of these effects is small — the Rezende 2013 and Valls 2021 data show 5–10 mg/dL reductions in LDL at 500 mg/day over 6–8 weeks, which is far less impressive than statins, berberine, or red yeast rice, and hesperidin should not be sold as a lipid-lowering agent except as a minor adjunct.

Hesperidin's exercise-performance signal (Martinez-Noguera 2019, 2020) is probably mediated by a combination of (1) improved endothelial NO signaling under the oxidative stress of hard exercise, which would preserve skeletal-muscle perfusion, (2) mild AMPK activation and PPAR-α signaling in skeletal muscle (mechanism still being characterized), and (3) antioxidant buffering that reduces exercise-induced inflammatory signaling and speeds recovery. None of these mechanisms individually would be expected to produce large performance gains, and the observed effect sizes (roughly 2–5% improvement in cycling time-trial performance) are consistent with this multi-factorial, small-magnitude story.

Hesperidin is essentially inactive at the classic neuro-receptor targets that concern users stacking multiple supplements. It does not bind meaningfully to GABA-A (unlike apigenin or the chrysin family), it does not significantly inhibit CYP3A4 at typical supplemental doses (the grapefruit-juice interaction is driven by furanocoumarins, not by citrus flavonoids), and it has minimal platelet-inhibitory activity at intakes achievable from food. At very high intakes (>1–2 g/day) or with concurrent aspirin/fish oil/NSAIDs, there is a theoretical additive bleeding risk, but the clinical signal is essentially zero in the published phlebology literature, which has used 1,000 mg/day MPFF in hundreds of thousands of patient-years.

Hesperidin is the signature flavanone glycoside of citrus fruit — specifically the 7-O-rutinoside of hesperetin — and it is the single most abundant flavonoid in the white pith and peel of sweet oranges, lemons, tangerines, and grapefruit. The compound accumulates at notable concentrations in citrus tissues that most consumers throw away, which is one reason why the therapeutic dose of hesperidin used in European phlebology (500 mg twice daily of micronized diosmin–hesperidin) is roughly an order of magnitude higher than what any realistic citrus-eating pattern delivers. Structurally, hesperidin is a flavanone, meaning it has a saturated C ring rather than the unsaturated C ring found in flavonols like quercetin or fisetin, and this saturation makes the molecule less electronically reactive and far less prone to the autoxidation chemistry that sometimes complicates flavonoid supplementation. Hesperidin is also unusual for the flavonoid world in that it is essentially odorless, tasteless, and water-insoluble in its native glycoside form, which paradoxically contributes to its poor oral bioavailability — the sugar moiety (rutinose) must be cleaved by colonic microbiota glycosidases before hesperetin aglycone can be absorbed across the gut wall. This absorption bottleneck is the central pharmacokinetic problem of hesperidin supplementation and it has spawned an entire generation of enhanced-bioavailability formulations including micronization (Daflon 500 / MPFF, used as a prescription phlebotonic in France and much of continental Europe), enzymatic deglycosylation to 2S-hesperidin (hesperidin-2-glucoside, roughly 3-4x more bioavailable than native hesperidin), and phytosome/phospholipid complexes.

BodyHackGuide covers hesperidin as the vascular endpoint of the flavonoid arc — the molecule in the polyphenol family with the cleanest human clinical evidence for endothelial function, blood pressure, and venous/lymphatic outcomes. Where quercetin has mast-cell and senolytic framing, where fisetin has its Mayo Clinic senolytic trial, where apigenin has CD38 inhibition and NAD+ salvage, and where pterostilbene has its resveratrol-analog bioavailability story, hesperidin owns the vascular endothelium and the microcirculation. The Orange Juice and Endothelial Function trials by Morand 2011 (PMID 21068346) and Buscemi 2012, the Rizza 2011 endothelial-function crossover, and the Salden 2016 dose-ranging trialtogether make hesperidin one of the most clinically validated flavonoids for flow-mediated dilation, a surrogate endpoint that correlates with long-term cardiovascular events. Layer on the Xiong 2019 blood pressure meta-analysis, the Valls 2021 lipid-profile data, and the decades of European prescribing experience with micronized purified flavonoid fraction (MPFF / Daflon) for chronic venous insufficiency and hemorrhoids — most of which is captured in the Martinez-Zapata 2020 Cochrane review on phlebotonics — and you have a compound with one of the best-evidenced benefit–risk profiles of any flavonoid on the supplement shelf. Hesperidin is cheap, safe at dietary and supplemental doses, and has been consumed at gram-level daily intakes by postmenopausal Mediterranean women for centuries without any signal of harm.

The mechanistic story centers on the endothelium and on NO (nitric oxide) signaling. Hesperetin aglycone — the active, absorbed form after rutinose cleavage by colonic bacteria — upregulates endothelial nitric oxide synthase (eNOS) and protects existing NO from superoxide quenching by reducing NADPH-oxidase expression in vascular smooth muscle. The net effect is vasodilation, improved flow-mediated dilation on brachial-artery ultrasound, and lower systolic blood pressure. The Milenkovic transcriptomic studies published across 2011–2016 (Milenkovic 2011, Milenkovic 2016) showed that a single 500 mg oral dose of hesperidin in healthy volunteers modulates the expression of hundreds of genes in peripheral blood mononuclear cells, with the biggest signals in inflammation and leukocyte transendothelial migration pathways. This transcriptomic fingerprint — dampening leukocyte adhesion to the vessel wall — maps cleanly onto the vein-wall stabilization and capillary-leak reduction that micronized diosmin–hesperidin achieves in chronic venous insufficiency. Hesperidin also has weak but measurable anti-inflammatory activity independent of endothelium, inhibiting NF-κB activation and reducing TNF-α, IL-6, and CRP modestly in some trials, and it appears to improve lipid metabolism marginally — the Rezende 2013 and Valls 2021 data show small but consistent reductions in total and LDL cholesterol at 500 mg/day doses over 6–8 weeks.

The venous-insufficiency indication deserves its own paragraph because it is the single application where hesperidin has regulatory approval as a prescription product in dozens of countries. Micronized Purified Flavonoid Fraction (MPFF) — sold as Daflon 500 in France, Venaflon and Diovenor elsewhere, Arvenum in Italy — is a 500 mg tablet containing 90% diosmin and 10% hesperidin (as hesperidin-rutinoside). The micronization process reduces particle size below 2 μm, dramatically increasing dissolution and absorption. Martinez-Zapata 2020's Cochrane review of phlebotonics (covering roughly 70 randomized trials in over 11,000 patients) concluded that MPFF produces moderate-quality evidence of benefit for lower-limb edema, cramps, restless legs, and the aching/heaviness complex of chronic venous insufficiency — benefits confirmed by the RELIEF study and the large prospective registries run by the French health system. Separately, MPFF is the best-evidenced medical therapy for symptomatic hemorrhoidal disease, with Perrin 2019 and earlier meta-analyses (Alonso-Coello 2006) showing reductions in bleeding, pain, and recurrence when MPFF is combined with fiber and hygiene interventions. The dose for venous and hemorrhoidal applications is typically 1,000 mg/day (500 mg twice daily) of MPFF, which is roughly 100 mg/day of hesperidin and 900 mg/day of diosmin — much higher than can be obtained from food.

A newer and nutritionally-relevant branch of the hesperidin literature is exercise performance and recovery, most of it driven by the Martinez-Noguera 2019and Martinez-Noguera 2020 studies on 2S-hesperidin (hesperidin-2-glucoside, marketed as Cardiose by HealthTech BioActives) in amateur cyclists. These trials showed modest but statistically significant improvements in maximal power output and time-trial performance in trained cyclists supplementing 500 mg/day of 2S-hesperidin for 8 weeks. Mechanism is presumed to be some combination of improved endothelial NO signaling under exercise stress, modest antioxidant buffering of exercise-induced oxidative stress, and possible effects on AMPK / PPAR-α and mitochondrial biogenesis (analogous to but much weaker than the exercise-mimetic signatures seen with higher-dose polyphenols in rodent studies). The effect size is small and not every study replicates, but the safety profile is impeccable and the performance claim does not require users to believe in anything more exotic than "better endothelial function during hard efforts."

Hesperidin is one of the few supplements on BodyHackGuide where the honest recommendation for most users is probably food first — aim for an orange a day, keep the white pith attached, and consider a glass of fresh-squeezed citrus juice with meals — and only move to supplementation if you have a specific indication (venous insufficiency, hemorrhoids, documented endothelial dysfunction, athletic performance goals). The supplement form that I would pick for most people is 2S-hesperidin (Cardiose) at 500 mg/day for its superior bioavailability, or MPFF/Daflon at 500 mg twice daily if you have clinical venous symptoms and want the prescription-grade formulation. Both forms are remarkably safe — there is essentially no ceiling-dose toxicity, no meaningful drug interactions apart from theoretical cautions with anticoagulants at very high intakes, and no evidence of harm at pregnancy-typical dietary intakes (though supplemental use in pregnancy should be discussed with an obstetrician since formal reproductive-toxicity data are limited). What you do NOT get from hesperidin is the senolytic activity of fisetin, the mast-cell stabilization of quercetin, the CD38 inhibition of apigenin, or the SIRT1 activation of pterostilbene — hesperidin sits in its own vascular and venous niche and should be selected accordingly, not treated as a generic "flavonoid supplement."

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Hesperidin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility